StockWatch
·
Breweries & Distilleries
Board Meeting27 Jul 2026, 06:30 pm

Imperial Blue lifts Tilaknagar revenue 165%, but PAT falls 64% to ₹32 Cr on integration costs

AI Summary

Tilaknagar Industries' first full quarter with the acquired Imperial Blue (IB) business transformed its scale but not yet its profit. Consolidated revenue from operations rose ~165% YoY to ₹2,252 Cr (net of ₹1,206 Cr excise duty, ~₹1,046 Cr), driven entirely by the IB division bought from Pernod Ricard for ₹3,442 Cr (completed Dec 2025). Consolidated PAT, however, fell to ₹31.6 Cr from ₹88.5 Cr a year ago — down ~64% reported, and still down ~30% even after excluding the ₹30.1 Cr exceptional charge for IB integration and transition costs. So the revenue explosion is inorganic and the bottom line went backwards on a like-for-like basis. The margin bridge explains the gap. Operating EBITDA of ~₹173 Cr translates to roughly 16% of net revenue — landing at the lower end of the 16–18% band management/brokerages have guided for FY27, consistent with the "margins near the low end" framing given near-term raw-material inflation. Below EBITDA, two acquisition-driven lines crush the print: finance costs jumped to ₹66.4 Cr (from ₹2.8 Cr a year ago) on the debt funding the deal, and depreciation rose to ₹45.5 Cr (from ₹7.3 Cr). Tax expense was nil. The result is a profit that is thin relative to the enlarged asset and debt base — the classic shape of an integration year. Sequentially the quarter reads better: revenue grew ~8% QoQ and the company swung back to a ₹31.6 Cr profit from a ₹14.9 Cr consolidated loss in Q4 FY26, when exceptional costs peaked. Operationally momentum is real — June 2026 saw a record 3.4 million cases and IB crossed 2 million cases in both May and June — which supports management's high-single to low-double-digit FY27 volume guide. Concurrent board actions this quarter fit the integration theme: approval of a composite amalgamation of two wholly-owned subsidiaries (Punjabexpo Breweries, Vahni Distilleries; appointed date 1 Apr 2026, pending NCLT), incorporation of a Nigeria WOS, and the addition of an independent director. No published Q1 street consensus was found, so the print is best judged against guidance rather than a number: margins met the low end, volumes are tracking, but reported profitability remains suppressed until integration costs roll off and the ₹3,442 Cr acquisition debt is worked down (management targets net debt/EBITDA below 1.0x by FY29). The auditor's qualified conclusion on the un-assessed ENA-plant impairment is an outstanding governance flag, not a P&L event this quarter.

Key Highlights

  • Consolidated revenue ₹2,252 Cr, up ~165% YoY (₹849 Cr) and ~8% QoQ — entirely inorganic, from the acquired Imperial Blue division; net of ₹1,206 Cr excise, net revenue ~₹1,046 Cr
  • Consolidated PAT ₹31.6 Cr vs ₹88.5 Cr YoY: −64% reported, and still −30% adjusted for the ₹30.1 Cr IB-integration exceptional charge
  • EBITDA ~₹173 Cr ≈ 16% of net revenue — at the lower end of the guided 16–18% FY27 band; reported margins compressed sharply on the excise-grossed topline
  • Bottom line hit by acquisition financing: finance costs ₹66.4 Cr (vs ₹2.8 Cr YoY) and depreciation ₹45.5 Cr (vs ₹7.3 Cr); tax expense nil
  • Sequential turnaround: swung to ₹31.6 Cr profit from a ₹14.9 Cr consolidated loss in Q4 FY26; EPS ₹1.28 (basic, consol)
  • Record volumes — 3.4 million cases in June 2026; Imperial Blue >2 million cases in May and June — supporting the high-single/low-double-digit FY27 volume guide
  • Board approved amalgamation of two WOS subsidiaries (pending NCLT) and a Nigeria subsidiary; auditor issued a QUALIFIED conclusion on un-assessed ENA-plant impairment
  • Standalone PAT ₹33.3 Cr on revenue ₹2,252 Cr (EPS ₹1.35) — broadly in line with consolidated